There are 412 resources available
151P - Exploring the predictive potential of [18F]FDG PET/CT for pathological complete response to neoadjuvant therapy: A prospective study
Presenter: Fabrizia Gelardi
Session: Lunch and Poster Display session
152P - Inflammatory breast cancer (IBC) in low and middle-income countries (LMICs): Knowledge, and practice patterns - The BRIDGES study
Presenter: Ilana Schlam
Session: Lunch and Poster Display session
153P - Correlation between disease free survival (DFS) endpoints and overall survival (OS) in elderly patients with human epidermal growth factor receptor 2-negative (HER2–) early breast cancer (eBC)
Presenter: Mark Robson
Session: Lunch and Poster Display session
154P - Validation of PREDICT tool version 2.2 in early-stage breast cancer (BC) patients enrolled in adjuvant trials by the Gruppo Italiano Mammella (GIM) and Mammella Intergruppo (MIG)
Presenter: Roberto Borea
Session: Lunch and Poster Display session
155P - From bench to equity: Closing the knowledge gap on racial differences in TNBC response to immunotherapy
Presenter: Oday Elmanaseer
Session: Lunch and Poster Display session
156P - The impact of Ki-67 on prognosis and chemotherapy benefit in breast cancer patients with ER-positive/HER2-negative micrometastatic disease in sentinel lymph nodes: A register-based cohort study
Presenter: Eva Tegnelius
Session: Lunch and Poster Display session
157TiP - A window-of-opportunity (WOO) trial of giredestrant +/- LHRHa vs anastrozole+LHRHa in premenopausal women with ER+/HER2- early breast cancer (EBC) (IBCSG 67-22; PREcoopERA)
Presenter: Elisabetta Munzone
Session: Lunch and Poster Display session
158TiP - Neoadjuvant abemaciclib and giredestrant trial in patients with ER-positive, HER2-negative early breast cancer (GIM31-Neo-AGILE trial)
Presenter: Claudia von Arx
Session: Lunch and Poster Display session
159TiP - TROPION-Breast04: Phase (ph) III study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC)
Presenter: Sibylle Loibl
Session: Lunch and Poster Display session
160P - Characteristics and outcomes of young breast cancer patients harboring BRCA pathogenic variants according to histologic subtype
Presenter: Elisa Agostinetto
Session: Lunch and Poster Display session